HONG KONG – Cellular Biomedicine Group Inc. has inked a partnership with Novartis AG to bring Kymriah (tisagenlecleucel) to market in China, putting it in a race with competing CAR T-cell therapy Yescarta (axicabtagene ciloleucel, Gilead Sciences Inc.), which is expected to soon start clinical trials in the country. (See BioWorld, Sept. 13, 2018.)